We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+7.46%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.91B
AUM Growth
-$296M
Cap. Flow
-$354M
Cap. Flow %
-18.46%
Top 10 Hldgs %
80.8%
Holding
37
New
1
Increased
1
Reduced
6
Closed
3

Top Buys

Rank Stock Value
1
ARDX icon
Ardelyx
ARDX
+$58.9M
2
ORKA
Oruka Therapeutics
ORKA
+$8.89M

Top Sells

Rank Stock Value
1
HPTX
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
+$109M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$97.6M
3
CVT
CVENT, INC.
CVT
+$74.9M
4
TSRO
TESARO, Inc.
TSRO
+$57.4M
5
SUPN icon
Supernus Pharmaceuticals
SUPN
+$42.8M

Sector Composition

Rank Sector Weight
1 Healthcare 71.57%
2 Communication Services 12.3%
3 Technology 8.35%
4 Consumer Discretionary 1.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$521M 27.18%
8,854,255
-1,000,000
-10% -$57.4M
GRPN icon
2
Groupon
GRPN
$1.05B
$222M 11.6%
2,208,648
– –
ARDX icon
3
Ardelyx
ARDX
$1.24B
$164M 8.58%
10,294,096
+4,672,897
+83% +$58.9M
SUPN icon
4
Supernus Pharmaceuticals
SUPN
$2.76B
$130M 6.78%
7,641,250
-3,008,750
-28% -$42.8M
EPZM
5
DELISTED
Epizyme, Inc
EPZM
$124M 6.45%
5,149,740
– –
OPWR
6
DELISTED
OPOWER INC COM STK (DE)
OPWR
$104M 5.41%
8,997,290
– –
CLVS
7
DELISTED
Clovis Oncology, Inc.
CLVS
$100M 5.23%
1,139,890
-1,139,891
-50% -$97.6M
CBIO
8
Crescent Biopharma
CBIO
$598M
$68.2M 3.56%
85,751
– –
DERM
9
DELISTED
Dermira, Inc.
DERM
$61.5M 3.21%
3,506,649
– –
NVRO
10
DELISTED
NEVRO CORP.
NVRO
$53.4M 2.79%
993,428
-376,471
-27% -$19.2M
VTAE
11
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$37.6M 1.97%
2,613,199
– –
HIVE
12
DELISTED
Aerohive Networks
HIVE
$32.7M 1.71%
4,681,455
-180,000
-4% -$1.15M
LOXO
13
DELISTED
Loxo Oncology, Inc
LOXO
$32.3M 1.69%
1,792,207
– –
TRVN
14
DELISTED
Trevena, Inc.
TRVN
$30.1M 1.57%
7,699
– –
TCON
15
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$21.4M 1.12%
9,448
– –
TRIV
16
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$21.1M 1.1%
3,945,191
– –
CRCM
17
DELISTED
CARE.COM, INC.
CRCM
$19.3M 1.01%
3,260,989
– –
LXRX icon
18
Lexicon Pharmaceuticals
LXRX
$1.03B
$19.2M 1%
2,382,286
– –
OREX
19
DELISTED
Orexigen Therapeutics, Inc.
OREX
$18.4M 0.96%
370,900
– –
ZSAN
20
DELISTED
Zosano Pharma Corporation
ZSAN
$15.6M 0.82%
3,084
– –
VIRX
21
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$14M 0.73%
22,187
– –
MM
22
DELISTED
MILLENNIAL MEDIA INC COM STK (DE)
MM
$13.3M 0.7%
8,224,752
– –
GYRE icon
23
Gyre Therapeutics
GYRE
$658M
$12.7M 0.67%
5,799
– –
ORKA
24
Oruka Therapeutics
ORKA
$5.34B
$11.8M 0.61%
+6,760
New +$8.89M
DZSI
25
DELISTED
DZS Inc. Common Stock
DZSI
$10.7M 0.56%
956,258
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q2 2015 Portfolio in Review

As of Q2 2015, NEA Management Company held 37 positions worth $1.91B, down 13% from $2.21B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

NEA Management Company withdrew a net $354M in Q2 2015, closing 3 positions and reducing 6 holdings. Its most notable exit was HYPERION THERAPEUTICS INC COM STK (DE), an estimated $109M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 62% a quarter earlier, followed by Communication Services and Technology.

Against the trend, NEA Management Company opened a new position in Oruka Therapeutics worth $11.8M.

  • NEA Management Company's largest Q2 2015 buy was Oruka Therapeutics: 6,760 shares worth $11.8M.
  • NEA Management Company added most to Ardelyx in Q2 2015, an estimated $58.9M increase.
  • NEA Management Company's biggest Q2 2015 reduction was Clovis Oncology, Inc., cutting an estimated $97.6M.
  • NEA Management Company fully exited HYPERION THERAPEUTICS INC COM STK (DE) in Q2 2015, selling an estimated $109M.
  • NEA Management Company's ten largest holdings make up 81% of its $1.91B portfolio in Q2 2015.
  • NEA Management Company opened 1 new position and closed 3 in Q2 2015.
  • NEA Management Company's portfolio value fell 13% quarter-over-quarter to $1.91B.

Based on NEA Management Company's 13F filing for Q2 2015, filed 15 Jul 2015.